Study S000779

A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen Deprivation Therapy (IMPACT-ADT)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07202247
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 60
Start: 2025-11-05
Primary completion: 2028-04-09
Lead sponsor: City of Hope Medical Center
Conditions: Prostate Carcinoma; Recurrent Prostate Carcinoma
Interventions: DRUG:Antiandrogen Therapy; BEHAVIORAL:Behavioral Intervention; PROCEDURE:Biospecimen Collection; PROCEDURE:Cardiac Computerized Tomographic Angiography; PROCEDURE:Computed Tomography; OTHER:Electronic Health Record Review; OTHER:Internet-Based Intervention; BEHAVIORAL:Lifestyle Counseling; OTHER:Medical Device Usage and Evaluation; OTHER:Nutritional Intervention; OTHER:Questionnaire Administration; RADIATION:Radiation Therapy; OTHER:Referral; DRUG:Semaglutide; OTHER:Short-Term Fasting; DRUG:Tirzepatide
Results posted: FALSE
Secondary identifiers: REGISTRY:NCI-2025-06197; OTHER:25332; NIH:P30CA033572

Registered primary outcomes

Changes in the 10-year risk of cardiovascular disease [At completion of 6 months of androgen deprivation therapy (ADT) and at 12 months follow up after completion of ADT]
Changes in the 10-year risk of cardiovascular disease [At completion of 6 months of ADT and at 12 months follow up after completion of ADT]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.